BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 28231386)

  • 41. [ALK protein expression and gene fusion in bronchoscopic specimens of lung adenocarcinoma].
    Liang X; Wang M; Zhang J; Luo Y; Zhang S; Wu S; Liu Y; Zeng X
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):501-4. PubMed ID: 25327654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
    Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
    Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry.
    Gruber K; Kohlhäufl M; Friedel G; Ott G; Kalla C
    J Thorac Oncol; 2015 Apr; 10(4):713-6. PubMed ID: 25789835
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
    Paik JH; Choi CM; Kim H; Jang SJ; Choe G; Kim DK; Kim HJ; Yoon H; Lee CT; Jheon S; Choe JY; Chung JH
    Lung Cancer; 2012 Jun; 76(3):403-9. PubMed ID: 22129856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
    Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
    J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
    Pekar-Zlotin M; Hirsch FR; Soussan-Gutman L; Ilouze M; Dvir A; Boyle T; Wynes M; Miller VA; Lipson D; Palmer GA; Ali SM; Dekel S; Brenner R; Bunn PA; Peled N
    Oncologist; 2015 Mar; 20(3):316-22. PubMed ID: 25721120
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement.
    Lin D; Zeng D; Chen C; Wu X; Wang M; Chen J; Lin H; Qiu X
    Oncol Res Treat; 2017; 40(1-2):27-33. PubMed ID: 28118634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma.
    Betz BL; Dixon CA; Weigelin HC; Knoepp SM; Roh MH
    Cancer Cytopathol; 2013 Sep; 121(9):489-99. PubMed ID: 23536384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers.
    Just PA; Cazes A; Audebourg A; Cessot A; Pallier K; Danel C; Vacher-Lavenu MC; Laurent-Puig P; Terris B; Blons H
    Lung Cancer; 2012 Jun; 76(3):309-15. PubMed ID: 22153831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
    Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
    World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Anaplastic lymphoma kinase-positive adenocarcinoma of lung: a cytopathologic analysis].
    Chen Y; Gao L; Wang Y; Gui X; Zhang H; Wang L; Gu L; Feng L; Wu J; Yang W; Song Y; Zeng H; Zhang J; Bai Q; Zhou X; Ping B
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):628-32. PubMed ID: 26705277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Copy number gain in recurrent anaplastic lymphoma kinase (ALK) rearrangement-lung adenocarcinoma in the pleural effusion.
    Abe H; Kawahara A; Azuma K; Murakami Y; Takase Y; Naito Y; Akiba J
    Diagn Cytopathol; 2018 Sep; 46(9):744-747. PubMed ID: 29637735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical application of immunocytochemical detection of ALK rearrangement on cytology slides for detection or screening of lung adenocarcinoma.
    Tanaka H; Tone K; Hayashi A; Morimoto T; Taima K; Tanaka Y; Nakagawa H; Takanashi S; Okumura K; Kurose A
    Lung Cancer; 2013 Jun; 80(3):289-92. PubMed ID: 23523007
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel
    Hirai N; Sasaki T; Okumura S; Sado M; Akiyama N; Kitada M; Takei H; Ohsaki Y
    Transl Lung Cancer Res; 2020 Apr; 9(2):257-268. PubMed ID: 32420065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics].
    Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J
    Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
    Singh A; Kumar R; Shetty O; Desai S; Rane S
    Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
    Cha YJ; Lee JS; Kim HR; Lim SM; Cho BC; Lee CY; Shim HS
    PLoS One; 2014; 9(7):e103333. PubMed ID: 25058391
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.